Our look is new. Our purpose is the same. Learn more about our brand evolution.
By Alex Kiselyov, CEO, Myocea, Inc. Myocea is a biotechnology startup with a focus on neuromuscular disorders. Our product pipeline is championed by the small molecule GBC0905 (Rebastinib) aimed at […]
by Barbara Zehetbauer-Hoehl, Vienna, Austria Three years ago, I developed a symptom called foot drop caused by my FSHD Type 2. The biggest loss, which came with losing my muscles […]
This Q&A is based on the December 9 webinar with Rabi Tawil, MD, and Ghinwa Dumyati, MD, from the University of Rochester Medical Center, and the January 15 webinar hosted […]
This month’s FSHD University webinar (video above) provided an outstanding, nontechnical explanation of magnetic resonance technology (MRI) and how it is being applied in the Fulcrum Therapeutics clinical trial […]
